Previous 10 | Next 10 |
Mechelen, Belgium and Paris, France, 15 OCTOBER 2020, 22.01 CET; regulated information –Servier and Galapagos NV (Euronext & NASDAQ: GLPG) report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA...
Additional data from Phase 2b/3 Selection trial evaluating filgotinib in 1,348 biologic-naïve or biologic-experienced for the treatment of moderate to severe active ulcerative colitis ((UC)) patients, demonstrated sustained efficacy and safety. Results were ...
-- Filgotinib 200mg Achieved Endoscopic, Histologic and Six-Month Corticosteroid-Free Remission at Week 58 with a Consistent Safety Profile -- -- Study Enrolled Biologic-Naïve and Biologic-Experienced Patients, a High Proportion of Whom Were Highly Refractory -- ...
-- Filgotinib 200mg Achieved Endoscopic, Histologic and Six-Month Corticosteroid-Free Remission at Week 58 with a Consistent Safety Profile -- -- Study Enrolled Biologic-Naïve and Biologic-Experienced Patients, a High Proportion of Whom Were Highly Refractory -- ...
Galapagos NV (GLPG) doses the first patient in its psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Toledo is a code name for a novel target class discovered by Galapagos for autoimmune and fibrotic diseases.CALOSOM...
TOL2/3 inhibitor most advanced compound in novel target class with dual action in inflammatory diseases Patient trials initiated with GLPG3970 in psoriasis, ulcerative colitis, and rheumatoid arthritis Toledo class target to be disclosed at Toledo Roundtable on 27 October 2020 ...
The following slide deck was published by Galapagos NV in conjunction with this event. For further details see: Galapagos ADR (GLPG) Investor Presentation - Slideshow
As expected, the European Commission approves Gilead Sciences' ([[GILD]] -0.5%) and collaboration partner Galapagos NV's ([[GLPG]] +3.2%) Jyseleca (filgotinib) for adults with moderate-to-severe rheumatoid arthritis who have failed to respond to or are intolerant of one or more disease-modify...
-- Jyseleca ® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today an...
-- Jyseleca ® Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...